CORC

在结果中检索

CORC

浏览/检索结果: 共19条，第1-10条 帮助

限定条件                
已选(0)清除 条数/页：   排序方式：
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer 期刊论文
2019, 卷号: 118, 页码: 169-177
作者:  Huober, Jens;  Holmes, Eileen;  Baselga, Jose;  de Azambuja, Evandro;  Untch, Michael
收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03
Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia 期刊论文
2019
作者:  Xu Binghe;  Kim Sung-Bae;  Inoue Kenichi;  Lee JuRueyJiuan;  Zhang Bo
收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03
Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer 期刊论文
2019, 卷号: 15, 期号: 21, 页码: 2489-2501
作者:  Iwata Hiroji;  Masuda Norikazu;  Kim Sung-Bae;  Inoue Kenichi;  Rai Yoshiaki
收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03
The age variation of HER2 immunohistochemistry positive rate in gastric cancer 会议论文
LABORATORY INVESTIGATION, 2018-03-01
作者:  Xi, Yangfeng;  Xu, Chen;  Liu, Yiqiang;  Yan, Xiaochu;  Huang, Chuansheng
收藏  |  浏览/下载：20/0  |  提交时间：2020/01/03
The age variation of HER2 immunohistochemistry positive rate in gastric cancer 期刊论文
2018, 卷号: 98, 页码: 311-312
作者:  Xi, Yangfeng;  Xu, Chen;  Liu, Yiqiang;  Yan, Xiaochu;  Huang, Chuansheng
收藏  |  浏览/下载：11/0  |  提交时间：2020/01/03
FRIEND: A randomized pilot study to compare the efficacy and tolerability of fulvestrant 500mg with exemestane as first line endocrine therapy for post-M ER positive HER2 negative ABC patients relapse after adjuvant non-steroidal aromatase inhibi 期刊论文
2017, 卷号: 28
作者:  Wang, J.;  Xu, B.;  Li, Q.;  Zhang, P.;  Yuan, P.
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03
FRIEND: A randomized pilot study to compare the efficacy and tolerability of fulvestrant 500mg with exemestane as first line endocrine therapy for post-M ER positive HER2 negative ABC patients relapse after adjuvant non-steroidal aromatase inhibi 会议论文
ANNALS OF ONCOLOGY, 2017-09-01
作者:  Wang, J.;  Xu, B.;  Li, Q.;  Zhang, P.;  Yuan, P.
收藏  |  浏览/下载：11/0  |  提交时间：2020/01/03
Outcomes of re-treatment with first-line Trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant Trastuzumab: A prospective multicenter study 期刊论文
2016, 卷号: 7, 期号: 31, 页码: 50643-50655
作者:  Xu, Binghe;  Hu, Xichun;  Zheng, Hong;  Wang, Xiaojia;  Zhang, Qingyuan
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04
A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment 期刊论文
2016, 卷号: 6, 页码: 33825
作者:  Du, F.;  Yuan, P.;  Zhao, Z. T.;  Yang, Z.;  Wang, T.
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04
A miRNA-based signature predicts development of disease recurrence in HER2 positive early breast cancer after adjuvant trastuzumab-based treatment. 期刊论文
2016, 卷号: 34, 期号: 15
作者:  Du, Feng;  Yuan, Peng;  Wang, Jiayu;  Ma, Fei;  Luo, Yang
收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04

©版权所有 ©2017 CSpace - Powered by CSpace